54
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Relative cost-effectiveness of using an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in Spain

, , , , , , , & show all
Pages 583-591 | Published online: 23 Nov 2015

Figures & data

Table 1 Unit costs in Euros at 2012/2013 prices

Figure 1 Expected probability of infants developing tolerance to cow’s milk by 18 months after starting a formula.

Abbreviations: AAF, amino acid formulae; eHCF, extensively hydrolyzed casein formula; IgE, immunoglobulin E; LGG, Lactobacillus rhamnosus GG.
Figure 1 Expected probability of infants developing tolerance to cow’s milk by 18 months after starting a formula.

Table 2 Expected levels of health care resource use and corresponding costs in Euros at 2012/2013 prices over 18 months from starting a formula

Table 3 Cost-effectiveness of eHCF + LGG versus eHCF and eHCF versus AAF

Figure 2 (A) Distribution of expected SNS costs over 18 months from starting a formula and expected probability of developing tolerance to cow’s milk by 18 months among IgE-mediated allergic infants, generated by 10,000 iterations of the model. (B) Distribution of expected SNS costs over 18 months from starting a formula and expected probability of developing tolerance to cow’s milk by 18 months among non–IgE-mediated allergic infants, generated by 10,000 iterations of the model.

Abbreviations: AAF, amino acid formulae; eHCF, extensively hydrolyzed casein formula; IgE, immunoglobulin E; LGG, Lactobacillus rhamnosus GG; SNS, Spanish National Health Service.
Figure 2 (A) Distribution of expected SNS costs over 18 months from starting a formula and expected probability of developing tolerance to cow’s milk by 18 months among IgE-mediated allergic infants, generated by 10,000 iterations of the model. (B) Distribution of expected SNS costs over 18 months from starting a formula and expected probability of developing tolerance to cow’s milk by 18 months among non–IgE-mediated allergic infants, generated by 10,000 iterations of the model.

Figure 3 (A) Probability of being cost-effective at different cost-effectiveness thresholds for IgE-mediated allergic infants, from the perspective of the SNS. (B) Probability of being cost-effective at different cost-effectiveness thresholds for non–IgE-mediated allergic infants, from the perspective of the SNS.

Abbreviations: AAF, amino acid formulae; eHCF, extensively hydrolyzed casein formula; IgE, immunoglobulin E; LGG, Lactobacillus rhamnosus GG; SNS, Spanish National Health Service.
Figure 3 (A) Probability of being cost-effective at different cost-effectiveness thresholds for IgE-mediated allergic infants, from the perspective of the SNS. (B) Probability of being cost-effective at different cost-effectiveness thresholds for non–IgE-mediated allergic infants, from the perspective of the SNS.

Table 4 Deterministic sensitivity analyses